Drugs / GEO-D03
last change Jan 2016 re-read 3 minutes ago

GEO-D03

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · GeoVax, Inc.

Trials 2

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01571960 Apr 2012 → Aug 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01909414 ? → Nov 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as GEO-D03 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01909414 ↗
1

NCT01571960 ↗

Modality Vaccine “GEO-D03 DNA vaccine” NCT01571960 ↗
Route Intramuscular “administered as a 1-mL IM injection into the deltoid” NCT01571960 ↗